CLSA bullish on Indian pharma, upgrades IPCA Laboratories to 'buy', downgrades Biocon, Ranbaxy

Jan 09 2014, 16:27 IST
Comments 0
CLSA upgrades IPCA Laboratories Ltd to 'Buy' from CLSA upgrades IPCA Laboratories Ltd to 'Buy' from "outperform".
SummaryCLSA upgrades IPCA Laboratories Ltd to 'Buy' from "outperform".

CLSA expects consensus upgrades for India's pharma sector on expectations of strong performance, as earnings will accelerate on back of its U.S. business and on improving domestic growth.

CLSA upgrades IPCA Laboratories Ltd to 'Buy' from "outperform" on expectations of strong earnings growth over FY14-16, while maintaining Lupin Ltd as its "conviction buy" on better return-ratios than peers.

However, the brokerage downgrades Biocon Ltd, Ranbaxy Laboratories Ltd to 'sell' from 'outperform' citing run up in valuations.

Shares of IPCA are up 2.02 percent, Ranbaxy and Biocon are down 0.23 percent, 2.6 percent respectively.

Ads by Google

More from Markets

Reader´s Comments
| Post a Comment
Please Wait while comments are loading...